Baricitinib + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cholangitis
Conditions
Primary Biliary Cholangitis
Trial Timeline
Mar 28, 2019 → Sep 26, 2019
NCT ID
NCT03742973About Baricitinib + Placebo
Baricitinib + Placebo is a phase 2 stage product being developed by Eli Lilly for Primary Biliary Cholangitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03742973. Target conditions include Primary Biliary Cholangitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07222332 | Phase 3 | Recruiting |
| NCT07222137 | Phase 3 | Recruiting |
| NCT05237388 | Phase 2 | Recruiting |
| NCT05723198 | Phase 3 | Recruiting |
| NCT04421027 | Phase 3 | Completed |
| NCT03843125 | Phase 3 | Terminated |
| NCT03899259 | Phase 3 | Completed |
| NCT03742973 | Phase 2 | Terminated |
| NCT03773978 | Phase 3 | Completed |
| NCT03570749 | Phase 2/3 | Completed |
| NCT03616964 | Phase 3 | Completed |
| NCT03616912 | Phase 3 | Terminated |
| NCT03334435 | Phase 3 | Completed |
| NCT03435081 | Phase 3 | Completed |
| NCT03334422 | Phase 3 | Completed |
| NCT03334396 | Phase 3 | Completed |
| NCT02758613 | Phase 1 | Completed |
| NCT02708095 | Phase 2 | Completed |
| NCT02265705 | Phase 3 | Completed |
| NCT01885078 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Biliary Cholangitis